Format

Send to

Choose Destination
Nat Commun. 2015 Mar 5;6:6456. doi: 10.1038/ncomms7456.

Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour.

Author information

1
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 10051, Taiwan.
2
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan.
3
Research Center for Tumor Medical Science, China Medical University, Taichung 40402, Taiwan.
4
Institute of Biotechnology, National Taiwan University, Taipei 10617, Taiwan.
5
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan.
6
Departments of Neurosurgery, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
7
Department of Industrial and System Engineering, Chung Yuan Christian University, Taoyuan 32023, Taiwan.
8
Institute of Physics, Academia Sinica, Taipei 11529, Taiwan.
9
Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
10
1] Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 10051, Taiwan [2] Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan [3] NTU Center for Genomic Medicine, National Taiwan University, Taipei 10051, Taiwan.
11
Ian Wark Research Institute, University of South Australia, Mawson Lakes, South Australia 5095, Australia.

Abstract

Anticancer therapies are often compromised by nonspecific effects and challenged by tumour environments' inherent physicochemical and biological characteristics. Often, therapeutic effect can be increased by addressing multiple parameters simultaneously. Here we report on exploiting extravasation due to inherent vascular leakiness for the delivery of a pH-sensitive polymer carrier. Tumours' acidic microenvironment instigates a charge reversal that promotes cellular internalization where endosomes destabilize and gene delivery is achieved. We assess our carrier with an aggressive non-small cell lung carcinoma (NSCLC) in vivo model and achieve >30% transfection efficiency via systemic delivery. Rejuvenation of the p53 apoptotic pathway as well as expression of KillerRed protein for sensitization in photodynamic therapy (PDT) is accomplished. A single administration greatly suppresses tumour growth and extends median animal survival from 28 days in control subjects to 68 days. The carrier has capacity for multiple payloads for greater therapeutic response where inter-individual variability can compromise efficacy.

PMID:
25739372
PMCID:
PMC4366491
DOI:
10.1038/ncomms7456
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center